Accès gratuit
Numéro
Med Sci (Paris)
Volume 22, Numéro 4, Avril 2006
Page(s) 405 - 410
Section M/S revues
DOI https://doi.org/10.1051/medsci/2006224405
Publié en ligne 15 avril 2006
  1. Feldmann H, Wahl-Jensen V, Jones SM, Stroher U. Ebola virus ecology : a continuing mystery. Trends Microbiol 2004; 12 : 433–7.
  2. Leroy EM, Rouquet P, Formenty P, et al. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004; 303 : 387–90.
  3. Rouquet P, Froment JM, Bermejo M, et al. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis 2005; 11 : 283–90.
  4. Baize S. A single shot against Ebola and Marburg virus. Nat Med 2005; 11 : 720–1.
  5. Chandran K, Sullivan NJ, Felbor U, et al. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005; 308 : 1643–5.
  6. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11 : 786–90.
  7. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci USA 1998; 95 : 5762–7.
  8. Volchkov VE, Becker S, Volchkova VA, et al. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 1995; 214 : 421–30.
  9. Volchkov VE, Volchkova VA, Muhlberger E, et al. Recovery of infectious Ebola virus from complementary DNA : RNA editing of the GP gene and viral cytotoxicity. Science 2001; 291 : 1965–9.
  10. Dutch RE, Jardetzky TS, Lamb RA. Virus membrane fusion proteins : biological machines that undergo a metamorphosis. Biosci Rep 2000; 20 : 597–612.
  11. Weissenhorn W, Dessen A, LJ Calder, et al. Structural basis for membrane fusion by enveloped viruses. Mol Membr Biol 1999; 16 : 3–9.
  12. Takada A, Robison C, Goto H, et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA 1997; 94 : 14764–9.
  13. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses : identification of receptor-deficient cell lines. J Virol 1998; 72 : 3155–60.
  14. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004, 78 : 5458–65.
  15. Feldmann H, Jones SM, Schnittler HJ, Geisbert T. Therapy and prophylaxis of Ebola virus infections. Curr Opin Investig Drugs 2005; 6 : 823–30.
  16. Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999; 5 : 423–6.
  17. Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128 : 163–8.
  18. Grolla A, Lucht A, Dick D, et al. Laboratory diagnosis of Ebola and Marburg hemorrhagic fever. Bull Soc Pathol Exot 2005; 98 : 205–9.
  19. Lupton HW, Lambert RD, Bumgardner DL, et al. Inactivated vaccine for Ebola virus efficacious in guinea pig model. Lancet 1980; 2 : 1294–5.
  20. Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8 : 503–7.
  21. Hevey M, Negley D, Pushko P, et al. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251 : 28–37.
  22. Gilligan JK, Geisbert JB, Jahrling PB, Anderson K. Assessment of protective immunity conferred by recombinant VACV to guinea pigs challenged with Ebola virus. In : Brown F, Burton D, Doherty P, et al., edS. Vaccines. Cold Spring Harbor (NY) : Cold Spring Harbor Laboratory Press, 1997 : 87–92.
  23. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003; 100 : 15889–94.
  24. Warfield KL, Swenson DL, Negley DL, et al. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004; 22 : 3495–502.
  25. Swenson DL, Warfield KL, Negley DL, et al. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23 : 3033–42.
  26. Vanderzanden L, Bray M, Fuller D, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998; 246 : 134–44.
  27. Xu L, Sanchez A, Yang Z, et al. Immunization for Ebola virus infection. Nat Med 1998; 4 : 37–42.
  28. Sullivan NJ, Sanchez A, Rollin PE, et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408 : 605–9.
  29. Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006; 346 : 394–401.
  30. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424 : 681–4.
  31. McKenna PM, McGettigan JP, Pomerantz RJ, et al. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res 2003; 1 : 229–37.
  32. Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005; 2 : e183.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.